Conflict of interest statement: The Genetic Pathology Evaluation Centre research unit (SL, TN) is the recipient of an unrestricted educational research grant from Sanofi-aventis Canada. TN holds shares in Bioclassifier LLC.
A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer†
Version of Record online: 26 SEP 2011
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 226, Issue 1, pages 97–107, January 2012
How to Cite
Ali, H. R., Dawson, S.-J., Blows, F. M., Provenzano, E., Leung, S., Nielsen, T., Pharoah, P. D. and Caldas, C. (2012), A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J. Pathol., 226: 97–107. doi: 10.1002/path.2976
- Issue online: 1 DEC 2011
- Version of Record online: 26 SEP 2011
- Accepted manuscript online: 26 JUL 2011 04:07AM EST
- Manuscript Accepted: 19 JUL 2011
- Manuscript Revised: 8 JUL 2011
- Manuscript Received: 8 MAY 2011
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.